Tectonic Therapeutic, Inc. (TECX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$19.42-4.33%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · TECX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
TECX — earnings miss
Dated 2026-05-07
Results of Operations and Financial Condition. On May 7, 2026, Tectonic Therapeutic, Inc. announced its financial results for the quarter ended March 31, 2026 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with
Why it matters: The trial tests whether TX45 lowers lung blood pressure in the more severe patient group. A clear result would guide the next study steps.
Watch forTopline results show that change in PVR, the main endpoint, improves versus placebo. This is in patients with baseline PVR above 3 WU.
Also watch forTopline results show no PVR improvement versus placebo in patients with baseline PVR above 3 WU. Or results come after early Q1 2027.
Why it matters: The six-person multiple-dose group tests repeat dosing. Its results help check the dose plan for later HHT trials.
Watch forTectonic reports that Part B supports the planned dose range. No serious or severe safety events were linked to treatment.
Also watch forPart B shows a serious or severe safety event. Or repeat-dose exposure does not support the planned dose range.
Why it matters: The trial will compare TX2100 with a placebo in moderate-to-severe HHT. It will track nosebleeds, hemoglobin, and blood support.
Supportive ifTectonic announces that the TX2100 Phase 2 trial has started in early 2027. The trial tests a placebo in moderate-to-severe HHT.
Worry ifThe trial has not started by the end of Q1 2027, or Tectonic reports a delay or a safety concern.
Why it matters: Tectonic reported $227.1 million in cash and a runway into Q1 2029. New cash or spending details can change that window.
Worry ifThe November 5 update keeps cash runway into Q1 2029 or longer. No new financing is needed for the stated trials.
Less concerning ifTectonic cuts its runway estimate to before Q1 2029 or announces new share sales to fund the stated trials.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$260 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $591 loss on $10,000 · 5.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,996 loss on $10,000 · 50.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.